(R)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-3-methyl-imidazo[1,2-a]-imidazol-2-one | 321656-72-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-3-methyl-imidazo[1,2-a]-imidazol-2-one
• 英文别名: (R)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-3-methyl-1-hydroimidazo[1,2-a]imidazol-2-one；(R)-3-(4-bromo-benzyl)-1-(3,5-dichloro-phenyl)-3-methyl-1H-imidazo[1,2-a]imidazol-2-one；(R)-3-(4-bromo-benzyl)-1-(3,5-dichloro-phenyl)-3-methyl-1H-imidazo[1,2-a]imidazole-2-one；(5R)-5-[(4-bromophenyl)methyl]-7-(3,5-dichlorophenyl)-5-methylimidazo[1,2-a]imidazol-6-one
• CAS: 321656-72-8
• 化学式: C₁₉H₁₄BrCl₂N₃O
• 分子量: 451.15
• InChiKey: TZLWATKWJLUXTA-LJQANCHMSA-N

物化性质

• 沸点：
  582.1±60.0 °C(Predicted)
• 密度：
  1.59±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  38.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-3-methyl-imidazo[1,2-a]-imidazol-2-one 在 N-碘代丁二酰亚胺 、 氢溴酸 、 4-甲基苯磺酸吡啶 、 三乙胺 、 环戊基溴化镁 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 溶剂黄146 为溶剂， 反应 4.92h， 生成 (R)-methanesulfonic acid 3-[5-(4-bromobenzyl)-7-(3,5-dichlorophenyl)-5-methyl-6-oxo-6,7-dihydro-5H-imidazo[1,2-α]imidazolyl-3-sulfonyl]propyl ester
  参考文献：
  名称：

  Second-Generation Lymphocyte Function-Associated Antigen-1 Inhibitors:  1H-Imidazo[1,2-α]imidazol-2-one Derivatives

  摘要：

  A novel class of lymphocyte function-associated antigen-1 (LFA-1) inhibitors is described. Discovered during the process to improve the physicochemical and metabolic properties of BIRT377 (1, Figure 1), a previously reported hydantoin-based LFA-1 inhibitor, these compounds are characterized by an imidazole-based 5,5-bicyclic scaffold, the 1,3,3-trisubstituted 1H-imidazo [1,2-alpha]imidazol-2-one (i.e. structure 3). The structure-activity relationship (SAR) shows that electron-withdrawing groups at C-5 on the imidazole ring benefit potency and that oxygen-containing functional groups attached to a C-5-sulfonyl or sulfonamide group further improve potency. This latter gain in potency is attributed to the interaction(s) of the functionalized sulfonyl/sulfonamide groups with the protein, likely polar-polar in nature, as suggested by SAR data. X-ray studies revealed that these bicyclic inhibitors bind to the I-domain of LFA-1 in a pattern similar to that of compound 1.

  DOI：

  10.1021/jm049657b
• 作为产物：
  描述：

  (R)-2-[(4',4'-dimethoxyethyl)aminocarbonyl]amino-2-(4-bromobenzyl)-N-(3,5-dichlorophenyl)-propionamide 在 三苯基二氯化膦 、 盐酸 作用下， 以 乙腈 、 水 为溶剂， 反应 2.0h， 生成 (R)-3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-3-methyl-imidazo[1,2-a]-imidazol-2-one
  参考文献：
  名称：

  Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides

  摘要：

  公开了一种改进的多步骤制备Formula I化合物的方法：其中R1到R3如本文所定义。 Formula I化合物抑制人类细胞间粘附分子与白细胞整合素的结合。因此，这些化合物在治疗炎症和免疫介导的细胞疾病方面是有用的。

  公开号：

  US20070173517A1

文献信息

• [EN] DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-SULFONYL]-PYRROLIDINE-2-CARBOXYLIC ACID AMIDE AS ANTI-INFLAMMATORY AGENTS<br/>[FR] DERIVES DE [6,7-DIHYDRO-5H-IMIDAZO[1,2-A]IMIDAZOLE-3-SULFONYL]-PYRROLIDINE-2 D'AMIDE D'ACIDE CARBOXYLIQUE EN TANT QU'AGENTS ANTI-INFLAMMATOIRES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2004041273A1

  公开（公告）日：2004-05-21

  Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

  6,7-二氢-5H-咪唑[1,2-α]咪唑-3-磺酰基]-吡咯烷-2-羧酸酰胺的衍生物表现出良好的抑制作用，可用于治疗炎症性疾病。
• DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a] IMIDAZOLE-3-SULFONIC ACID
  申请人：Barry Patrick John

  公开号：US20060264472A1

  公开（公告）日：2006-11-23

  Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

  6,7-二氢-5H-咪唑[1,2-a]咪唑-3-磺酸的衍生物对CAM和白细胞整合素的相互作用具有良好的抑制作用，因此在炎症性疾病的治疗中具有用处。
• Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides
  申请人：Wang Xiao-Jun

  公开号：US20060025447A1

  公开（公告）日：2006-02-02

  Disclosed is a multi-step process for preparing a compound of Formula I: wherein R 1 to R 3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a result, these compounds are useful in the treatment of inflammatory and immune cell-mediated diseases.

  公开了一种制备化合物I的多步过程：其中R1至R3如本文所定义。化合物I的公式抑制人体细胞间粘附分子与白细胞整合素的结合。因此，这些化合物在治疗炎症和免疫细胞介导的疾病中是有用的。
• Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20040127534A1

  公开（公告）日：2004-07-01

  Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

  6,7-二氢-5H-咪唑[1,2-a]咪唑-3-磺酰胺基-丙酰胺的衍生物在抑制细胞黏附分子（CAMs）和白细胞整合素相互作用方面表现良好，因此在治疗炎症性疾病方面具有用处。
• Derivatives of [6,7-dihydro-5H- Imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
  申请人：Kelly Alfred Terence

  公开号：US20050054704A1

  公开（公告）日：2005-03-10

  Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

  6,7-二氢-5H-咪唑[1,2-a]咪唑-3-磺酰基-吡咯烷-2-羧酸酰胺的衍生物表现出良好的抑制作用，可以用于治疗炎症性疾病，因其可以抑制细胞粘附分子和白细胞整合素之间的相互作用。